Scilex Holding (SCLXW) Change in Account Payables (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Change in Account Payables of $15.8 million in Q1 2026, up 794.34% quarter-over-quarter from $1.8 million in Q4 2025, and up 208.35% on a YoY basis from $5.1 million in Q1 2025.
Scilex Holding (SCLXW) Change in Account Payables (2022 - 2026) Analysis & Trends
Scilex Holding's Change in Account Payables history runs 5 years deep, the most recent figure standing at $15.8 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 208.35% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $23.8 million (up 111.0% YoY), while the FY2025 annual figure was $13.1 million, up 76.86% from the prior year.
- Change in Account Payables was $15.8 million for Q1 2026 at Scilex Holding, up from $1.8 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $15.8 million in Q1 2026 to a low of -$612000.0 in Q2 2024.
- Historically, Change in Account Payables has averaged $3.5 million across 5 years, with a median of $2.0 million in 2023.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables surged 5313.66% in 2023, then sank 126.23% in 2024.
- A 5-year view of Change in Account Payables shows it stood at -$161000.0 in 2022, then soared by 5313.66% to $8.4 million in 2023, then plunged by 38.61% to $5.2 million in 2024, then sank by 65.69% to $1.8 million in 2025, then soared by 794.34% to $15.8 million in 2026.
- The last three Change in Account Payables figures came in at $15.8 million (Q1 2026), $1.8 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 571.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -67.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 409.00 Mn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 15.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.81 Mn |
| Mar 31, 2026 | 15.81 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Dec 31, 2024 | 5.15 Mn |
| Dec 31, 2024 | 5.15 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | -612,000.00 |
| Jun 30, 2024 | -612,000.00 |
| Mar 31, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 8.39 Mn |
| Dec 31, 2023 | 8.39 Mn |